Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/17/2014 -- Hotpennystocknews.com issues special report on - Two Rivers (TURV), Provectus Biopharmaceuticals (OTCMKTS:PVCT)
Two Rivers (TURV) has developed and operates a revolutionary new water business model suitable for arid regions in the Southwestern United States whereby the Company synergistically integrates irrigated farming and wholesale water distribution into one company, utilizing a practice of rotational farm fallowing. Rotational farm fallowing, as it applies to water, is a best methods farm practice whereby portions of farm acreage are temporarily fallowed in cyclic rotation to give soil an opportunity to reconstitute itself. As a result of fallowing, an increment of irrigation water can be made available for municipal use without permanently drying up irrigated farmland.
Collaborative rotational farm fallowing agreements between farmers and municipalities make surplus irrigation water available for urban use during droughts and, conversely, make surplus urban water available for irrigation during relatively wet periods. The Company produces and markets high-value vegetable and fodder crops on its irrigated farmland and provides wholesale water distribution through farm fallowing agreements in its initial area of focus on the Arkansas River and its tributaries on the Southern Front Range of Colorado.
TURV is +0.12 - +13.64% from the previous close of $0.88. It traded between $0.88 - 1.00 with total traded volume of 12000 shares.At Current Market Price, TURV is in distance of +27.76% from its 50-day Moving Average price of $0.7827 and +19.07% from its 200-day Moving Average price of $0.8399.
Click here to receive FREE breaking news email alerts for Two Rivers (TURV)
Provectus Biopharmaceuticals (OTCMKTS:PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT ended lower -5.00% and complete the day at $2.66. The total number of shares changed hands during the day was 143.37 million. After opening at $2.83, the stock hit as high as $2.84. However, it traded between $0.55 and $3.00 over the last twelve months.
Has PVCT Found The Bottom and Ready To Move Up? Find Out Here.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)